ArticleJournal of orthopaedic surgery and research2026
Dexmedetomidine mitigates postoperative delirium after hip fracture surgery in elderly patients by modulating miR-107 expression.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPostoperative delirium (POD) in elderly hip fracture patients has a poor prognosis, and the effect and mechanism of dexmedetomidine (Dex) combined with pericapsular nerve group (PENG) block on POD are unclear. To explore the improvement effect of Dex combined with PENG block on POD in elderly hip fracture patients and the regulatory role of miR-107.
methodsEighty-four elderly hip fracture patients (July 2022-December 2023) were divided into PENG block group (n = 28), Dex group (n = 27), and combined group (n = 29). NRS, MMSE, and POD incidence (CAM) were evaluated at T0 (preoperative), T1 (postoperative day 1), and T2 (postoperative day 7); serum miR-107 expression was detected and correlated. A mouse POD model and LPS-induced SH-SY5Y cell model were established; Morris water maze, Y-maze, open field test, ROC, logistic, CCK-8, ELISA, qPCR, and dual-luciferase assay were used for mechanism verification.
resultsNo significant differences were found among the three groups at T0. At T1 and T2, the combined group had lower NRS scores, higher MMSE scores, lower POD incidence (P < 0.05), and upregulated serum miR-107 (P < 0.001). miR-107 was positively correlated with MMSE (P < 0.001) and negatively correlated with NRS (P < 0.05). Animal/cell experiments showed Dex upregulated miR-107, inhibited FBXW7 and inflammatory factors, and improved cognition; miR-107 directly targeted FBXW7.
conclusionsDex combined with PENG block alleviates POD in elderly hip fracture patients by upregulating miR-107 to inhibit FBXW7 and neuroinflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.